 |
|
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong
Clin Mol Hepatol. 2021;27(2):273-277. Published online 2021 Feb 1 DOI: https://doi.org/10.3350/cmh.2021.0019
|
|
Citations to this article as recorded by
 Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim
Clinical and Molecular Hepatology.2023; 29(2): 482. CrossRef The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?
Wen-Juei Jeng, Grace Lai-Hung Wong
Hepatology Communications.2023; 7(3): e0060. CrossRef Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma
Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee
Clinical and Molecular Hepatology.2023; 29(3): 794. CrossRef A global investment case for hepatitis B elimination: a modelling study
Christopher P Seaman, Phillip Luong, Yinzong Xiao, Romesh Abeysuriya, Jess Howell, Margaret Hellard, Nick Scott
The Lancet Gastroenterology & Hepatology.2023; 8(10): 932. CrossRef Correlation between contrast-enhanced ultrasound perfusion parameters and EphB4 expression in hepatocellular carcinoma lesions
Chen-ZhuoYa Sheng, Gen-Xin Yao, Xin-Rong Zhang, Dong Li
World Chinese Journal of Digestology.2021; 29(18): 1084. CrossRef Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
Cancers.2021; 13(14): 3424. CrossRef
|